Salubris (Suzhou) Pharmaceutical Co., Ltd. announced a private placement of CNY 26 million on January 18, 2023. The transaction will include participation from returning investor, Shenzhen Salubris Pharmaceuticals Co., Ltd. The company's registered capital will increase from CNY 212,430,446.29 to CNY 238,430,446.29. The transaction has been approved by the 35th meeting of the fifth board of directors of the company.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
31.92 CNY | +0.31% | +2.11% | -2.27% |
Apr. 23 | Salubris Pharmaceuticals' Q1 Profit Falls 5% Despite 23% Rise in Operating Income | MT |
Apr. 23 | Salubris Pharmaceuticals to Raise Capital of US Unit by $35 Million | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.27% | 4.81B | |
+19.98% | 43.48B | |
+20.67% | 22.65B | |
+14.56% | 14.73B | |
+14.32% | 13.79B | |
+44.72% | 12.04B | |
-8.37% | 7.08B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+11.90% | 5.47B |
- Stock Market
- Equities
- 002294 Stock
- News Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Salubris Pharmaceutical Co., Ltd. announced that it expects to receive CNY 26 million in funding from Shenzhen Salubris Pharmaceuticals Co., Ltd.